The Meloxicam Market is estimated at US$8.2 billion in 2026 and is projected to grow at a CAGR of 7% to reach US$14.1 billion by 2034.
Relevant uses and settings include arthritis management, pain therapy, hospital formulary use, outpatient care, primary care prescribing, and chronic inflammation support pathways. Commercial considerations include generic price pressure, gastrointestinal safety considerations, reimbursement scrutiny, and competition from alternative nonsteroidal therapies and multimodal pain approaches.
This product will be delivered within 1-3 business days.
Market Overview
The Meloxicam Market covers pharmaceutical products containing meloxicam used for pain relief and anti inflammatory treatment across musculoskeletal, arthritis, and general supportive care settings.Relevant uses and settings include arthritis management, pain therapy, hospital formulary use, outpatient care, primary care prescribing, and chronic inflammation support pathways. Commercial considerations include generic price pressure, gastrointestinal safety considerations, reimbursement scrutiny, and competition from alternative nonsteroidal therapies and multimodal pain approaches.
Key Companies Analysed
- Boehringer Ingelheim
- Viatris
- Teva Pharmaceutical
- Sun Pharmaceutical
- Dr. Reddy's
- Aurobindo Pharma
- Cipla
- Hikma Pharmaceuticals
- Zydus Lifesciences
- Apotex
- Lupin
- Sandoz
- Torrent Pharmaceuticals
- Alembic Pharmaceuticals
- Amneal Pharmaceuticals
- Macleods
- Pfizer
- Bayer
- Fresenius Kabi
- Aspen Pharmacare
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Meloxicam Market Overview
3. Meloxicam Market Dynamics
4. Meloxicam Market Strategic Analysis
5. Global Meloxicam Market Size, Share and Forecast, 2025-2034
6. North America Meloxicam Market Outlook to 2034
7. Europe Meloxicam Market Outlook to 2034
8. Asia-Pacific Meloxicam Market Outlook to 2034
9. Middle East and Africa Meloxicam Market Outlook to 2034
10. South and Central America Meloxicam Market Outlook to 2034
11. Meloxicam Market Competitive Landscape
12. Appendix
Companies Mentioned
- Boehringer Ingelheim
- Viatris
- Teva Pharmaceutical
- Sun Pharmaceutical
- Dr. Reddy's
- Aurobindo Pharma
- Cipla
- Hikma Pharmaceuticals
- Zydus Lifesciences
- Apotex
- Lupin
- Sandoz
- Torrent Pharmaceuticals
- Alembic Pharmaceuticals
- Amneal Pharmaceuticals
- Macleods
- Pfizer
- Bayer
- Fresenius Kabi
- Aspen Pharmacare
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value in 2026 | 8.2 Billion |
| Forecasted Market Value by 2034 | 14.1 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
